as 01-21-2025 4:00pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | CELEBRATION |
Market Cap: | 458.5M | IPO Year: | 2015 |
Target Price: | $21.20 | AVG Volume (30 days): | 492.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.11 | EPS Growth: | N/A |
52 Week Low/High: | $4.20 - $9.76 | Next Earning Date: | 11-12-2024 |
Revenue: | $24,489,000 | Revenue Growth: | 47.85% |
Revenue Growth (this year): | -24.57% | Revenue Growth (next year): | 384.62% |
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Simply Wall St.
a month ago
MT Newswires
a month ago
GlobeNewswire
a month ago
Pharma Voice
a month ago
GlobeNewswire
2 months ago
Simply Wall St.
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.